Key result
Celecoxib use is now subject to new restrictions and valdecoxib has been withdrawn from the market following the earlier withdrawal of rofecoxib.
Answers are grounded in this paper and cite their sources.
Highlights the regulatory actions regarding COX-2 inhibitors, including the withdrawal of rofecoxib and valdecoxib.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
José Cotter (2005) studied this question. Celecoxib use is now subject to new restrictions and valdecoxib has been withdrawn from the market following the earlier withdrawal of rofecoxib.
Synapse has enriched 10 related papers. Consider them for comparative context: